AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06563323
Drug: Guselkumab
RxNorm normalized name: Guselkumab
DrugBank: Guselkumab (DB11834)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects with PG will be treated with 100 mg in a pre-filled syringe to be injected subcutaneously every 4 weeks for 28 weeks.
Trial: NCT05446311
Drug: Dinalbuphine sebacate
RxNorm normalized name: Dinalbuphine sebacate
DrugBank: Dinalbuphine sebacate (DB15341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After giving the birth, subjects are intramuscularly injected with a single dose of 150 mg of dinalbuphine sebacate (DS). DS is a prodrug of nalbuphine. After injeciton, DS are released to blood stream and hydrolyzed immediately. The onset of action is 12 to 24 hours and the analgesic effect can last about 5 to 7 days.
Trial: NCT05673694
Drug: EG017
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: According to the dosage group of the program, once a day.
Trial: NCT05658692
Drug: Vasoactive drug therapy
RxNorm normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021.
Trial: NCT04379011
Drug: Brivaracetam
RxNorm normalized name: Brivaracetam
DrugBank: Brivaracetam (DB05541)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Escalating brivaracetam dose to 150 mg twice daily for 3 months
Trial: NCT04922593
Drug: LY03010; paliperidone palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
Trial: NCT04922593
Drug: INVEGA SUSTENNA
RxNorm normalized name: Invega Sustenna
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: INVEGA SUSTENNA (234 mg, 156 mg) is manufactured by Janssen Pharmaceuticals, Inc and is commercially available.
Trial: NCT06572553
Drug: Faricimab
RxNorm normalized name: Faricimab
DrugBank: Faricimab (DB15303)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Faricimab (faricimab-svoa; Vabysmo), a bispecific antibody that inhibits both VEGF-A and Ang-2, was developed by Roche/Genentech, and dual-pathway inhibition may provide stronger and longer-lasting efficacy in the treatment of retinal vascular disease relative to anti-VEGF therapy alone.
Trial: NCT05897216
Drug: CKD-383
RxNorm normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD, PO
Trial: NCT06663059
Drug: Adebrelimab combined with albumin-bound paclitaxel and cisplatin 2 cycle
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each treatment cycle is 3 weeks long (Q3W), with a total of 2 cycles. Adebrelimab: 1200 mg once on Day 1, administered intravenously, Q3W. Albumin-bound Paclitaxel: 130 mg/m² on Day 1 and Day 8, administered intravenously, Q3W.~Cisplatin: 75 mg/m² on Day 1, administered intravenously, Q3W.~Drug infusion should follow this sequence:~Adebrelimab → Albumin-bound Paclitaxel → Cisplatin, with a minimum interval of 30 minutes between each infusion.
Trial: NCT06663059
Drug: Adebrelimab combined with albumin-bound paclitaxel and cisplatin 4 cycle
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each treatment cycle is 3 weeks long (Q3W), with a total of 4 cycles. Adebrelimab: 1200 mg once on Day 1, administered intravenously, Q3W. Albumin-bound Paclitaxel: 130 mg/m² on Day 1 and Day 8, administered intravenously, Q3W.~Cisplatin: 75 mg/m² on Day 1, administered intravenously, Q3W.~Drug infusion should follow this sequence:~Adebrelimab → Albumin-bound Paclitaxel → Cisplatin, with a minimum interval of 30 minutes between each infusion.
Trial: NCT06663839
Drug: Biological NILK-2301
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatments will be administered every two weeks in 28-day cycles for up to 12 months until disease progression, unacceptable toxicity, or Investigator/patient decision to withdraw study consent. Should evidence emerge showing that treatment beyond one year may prolong benefit in responding patients, the protocol will be amended to ensure that these responding patients may continue with the study treatment beyond 12 months until disease progression.
Trial: NCT06662669
Drug: YL-13027
RxNorm normalized name: dibenzothiazol-2-yl disulfide
DrugBank: 2,2'-Dibenzothiazyl disulfide (DB14201)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YL-13027 is a small molecule inhibitor of the TGF-βRI target.
Trial: NCT06662669
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine is a pyrimidine antineoplastic chemotherapeutic agent.
Trial: NCT06662669
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel for Injection (albumin bound) is a chemotherapeutic agent that acts as an antitumor agent by inhibiting tumor cell mitosis
Trial: NCT05591417
Drug: Intravenous morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous morphine 0.1 mg/kg
Trial: NCT06662877
Drug: Albumin-bound Paclitaxel + Tegafur Gimeracil Oteracil (S-1) + Anlotinib
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Albumin-bound Paclitaxel, 125mg/m2,iv.drip,d1,d8,Q3W +Tegafur Gimeracil Oteracil (S-1) 40-60mg,p.o,bid,d1-d14,Q3W+Anlotinib 10mg,p.o,d1-d14,Q3W
Trial: NCT06272916
Drug: Aminophylline , magnesium sulphate and placebo
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Comparison of the Effect of Aminophylline, Magnesium Sulphate and Placebo in Prevention of Post Dural Puncture Headache in Parturient Undergoing Caesarean Section
Trial: NCT04064697
Drug: Valganciclovir
RxNorm normalized name: Valganciclovir
DrugBank: Valganciclovir (DB01610)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The experimental intervention consists of taking the treatment Valganciclovir 900 mg morning and evening for 3 weeks
Trial: NCT04876027
Drug: GLP-1 RAs
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: GLP-1 receptor agonist is a glucagon-like peptide 1 analog, which is related to improving blood sugar control, weight loss and appetite suppression, and reducing cardiovascular risk.
Trial: NCT06463847
Drug: UC-MSCs
RxNorm normalized name: UC-MSCs
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this study, three dose groups are preset, which are low-dose group: 5×10\^6 cells/2.5mL; medium-dose group: 1×10\^7 cells/2.5mL; high-dose group: 2×10\^7cells/2.5mL, 9 to 18 subjects will be recruited, and will be sequential from the low-dose group to the high-dose group according to the 3+3 dose escalation principle. At least 3 subjects are enrolled in each group for the safety and tolerability test of single administration. After the last subject in each dose group completes the DLT observation period, the sponsor and the researcher jointly confirm the safety tolerance of the subjects in the previous dose group, and only after the safe tolerance is determined can the subjects enter the next dose group, so as to evaluate the safety and tolerance of human umbilical cord mesenchymal stem cell injection in the treatment of knee osteoarthritis. Recommend appropriate cell therapy dose (RP2D) for Phase II clinical trials.
Trial: NCT04832204
Drug: Apatinib and Camrelizumab for Injection
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib 250mg, Qd, oral administration,SHR-1210 200mg, q3w one week later, intravenous administration, continuous administration until the disease progresses or an intolerable adverse reaction occurs.
Trial: NCT05745740
Drug: RC48-ADC
RxNorm normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RC48-ADC 1.5/2.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 14-day cycle
Trial: NCT05745740
Drug: Pyrotinib
RxNorm normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrotinib 400 mg by oral once a day.
Trial: NCT05025293
Drug: sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100ml NaCl 9mg/ml administered intravenously
Trial: NCT05968612
Drug: Lumacaftor 200 mg/Ivacaftor 125 mg Film-Coated Tablet
DrugBank: Ivacaftor (DB08820)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Film-coated tablet administered orally.
Trial: NCT05968612
Drug: Lumacaftor 200 mg Film-Coated Tablet Formulation
RxNorm normalized name: ivacaftor
DrugBank: Lumacaftor (DB09280)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Film-coated tablet administered orally.
Trial: NCT05427149
Drug: 25 mg MgSO4 (Magnezyum Sulfat %15, Biofarma, Istanbul, Turkey)
RxNorm normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: It will be evaluated whether there is postpinal shivering in the cases.
Trial: NCT02503280
Drug: Autologous hMSCs
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous hMSCs: 40 million cells/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 2 x 10\^8 (200 million) hMSCs.
Trial: NCT02503280
Drug: Autologous Human C-Kit CSCs II
RxNorm normalized name: angiotensin II acetate, human
DrugBank: (2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE (DB07955)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous hMSCs PLUS autologous C-Kit hCSCs: Mixture of 39.8 million hMSCs and 0.2 million C-Kit hCSCs/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 1.99 x 10\^8 (199 million) hMSCs and 1 million C-Kit hCSCs.
Trial: NCT05604729
Drug: Botulinum toxin type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Botulinum Neurotoxin type A
Trial: NCT05481112
Drug: Extended-Release Buprenorphine Injection
RxNorm normalized name: Buprenorphine Extended-Release Injection
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Extended-release buprenorphine (XR-B, Sublocade) is manufactured by Indivior. XR-B consists of a depot injectable formulation in polymeric solution to the abdomen and releases buprenorphine over 28-days (4-weeks) by diffusion as the polymer biodegrades.
Trial: NCT05409924
Drug: ATR-258
RxNorm normalized name: Atr-101 free base
DrugBank: Nevanimibe (DB16254)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Ascending Dose
Trial: NCT05409924
Drug: ATR-258
RxNorm normalized name: Atr-101 free base
DrugBank: Nevanimibe (DB16254)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple Ascending Dose
Trial: NCT05409924
Drug: ATR-258
RxNorm normalized name: Atr-101 free base
DrugBank: Nevanimibe (DB16254)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeat Dose
Trial: NCT06460194
Drug: Botuinum toxin
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Injection of botulinum toxin in the palm of the hand
Trial: NCT00893490
Drug: Mitomycin C (MMC)
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 minute MMC application
Trial: NCT00411307
Drug: OROS hydromorphone HCI
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04863950
Drug: Lomustine
RxNorm normalized name: Lomustine
DrugBank: Lomustine (DB01206)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For surgical cohort patients, lomustine will be initiated (C1D1) within 6 weeks of surgery as soon as patient is deemed by the investigator (or designee) to be recovered enough for chemotherapy. Initiation of lomustine must be initiated within 6 weeks. If patient cannot be safely initiated on lomustine within this timeframe then they will be replaced.~For non-surgical cohort patients (the decision for surgery is made independent of study participation), lomustine will be initiated on C1D1.~For both cohorts, lomustine will be administered as 110 mg/m2 PO once every 6 weeks.
Trial: NCT04863950
Drug: Imipramine Hydrochloride
RxNorm normalized name: Imipramine Hydrochloride
DrugBank: Imipramine (DB00458)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For the surgical cohort, imipramine hydrochloride will be initiated within a minimum of 16 days to a maximum of 3 weeks prior to surgery. Imipramine hydrochloride will be administered as 50mg PO (oral) QHS (at bedtime) for 4 days followed by a dose increase (taper-up) of 50mg/day every fourth day to attain a maximum dose of 200mg/day in 16 days.~For non-surgical cohort patients (the decision for surgery is made independent of study participation), imipramine hydrochloride will be initiated on Cycle 1 Day 1. Imipramine hydrochloride will be administered as 50mg PO (oral) QHS (at bedtime) for 4 days followed by a dose increase (taper-up) of 50mg/day every fourth day, if tolerated, to attain a maximum dose of 200mg/day in 16 days.
Trial: NCT05071417
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Usual treatment with semaglutide. Dose 0.5 - 1mg weekly, subcutaneous, weekly
Trial: NCT05904964
Drug: Disitamab vedotin
RxNorm normalized name: Disitamab vedotin
DrugBank: Disitamab vedotin (DB17208)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disitamab Vedotin 2mg/kg was injected every 2 weeks,
Trial: NCT03178071
Drug: Lorlatinib
RxNorm normalized name: LORLATINIB
DrugBank: Lorlatinib (DB12130)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oral tablets, administered daily, continuously
Trial: NCT04908813
Drug: HLX22
RxNorm normalized name: Lanadelumab
DrugBank: Lanadelumab (DB14597)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV Q3W D1
Trial: NCT04908813
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV Q3W D1
Trial: NCT04908813
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV Q3W D1
Trial: NCT06364826
Drug: Sintilimab, bevacizumab, gemcitabine
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: This is a prospective, single-center, single-arm, phase II clinical study. The study was intended to include patients with locoregionally advanced nasopharyngeal cancer identified by histology or cytology, who signed informed consent and met the screening criteria to enter the study. Patients will receive induction therapy (sintilimab + bevacizumab + gemcitabine, Q3W, 3 cycles) followed by IMRT+ Sintilimab. Consolidation therapy with sintilimab continued after radiotherapy until disease progression, intolerable toxicity, death, or the subject's decision to withdraw from the study, with a total treatment period of no more than 12 cycles.
Trial: NCT05976334
Drug: [14C] Subasumstat
DrugBank: Subasumstat (DB16406)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[14C\] Subasumstat IV infusion.
Trial: NCT05976334
Drug: Subasumstat
RxNorm normalized name: Subasumstat
DrugBank: Subasumstat (DB16406)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subasumstat IV infusion.
Trial: NCT06393361
Drug: Chidamide; Decitabine; Anti-PD-1 Antibody
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chidamide 10mg/day, day1-4; 20mg/day, day 8,11, 15, 18. Decitabine 10mg/day, day1-5. Physicians will decide which immune checkpoint inhibitors will be used during treatment.
Trial: NCT06393361
Drug: Brentuximab Vedotin, anti-PD-1 antibody.
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab Vedotin 1.8mg/kg d1, anti-PD-1 antibody d1. Physicians will decide which immune checkpoint inhibitors will be used during treatment.
Trial: NCT06669754
Drug: Deucrictibant
RxNorm normalized name: Deucrictibant
DrugBank: Deucrictibant (DB18303)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deucrictibant 40mg extended-release tablet for once daily oral use
Trial: NCT06669247
Drug: Linvoseltamab
RxNorm normalized name: Linvoseltamab
DrugBank: Linvoseltamab (DB17447)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered per protocol
Trial: NCT06669247
Drug: REGN7945+Linvoseltamab
RxNorm normalized name: Linvoseltamab
DrugBank: Linvoseltamab (DB17447)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered per protocol
Trial: NCT04646395
Drug: Tafasitamab
RxNorm normalized name: Tafasitamab
DrugBank: Tafasitamab (DB15044)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 200 mg powder for reconstitution with 5 ml water for injection
Trial: NCT04646395
Drug: Acalabrutinib
RxNorm normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg hard gelatin capsules
Trial: NCT03995004
Drug: Dexamethasone Sodium Sulphate 4mg/1mL
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone is a glucocorticoid commonly used in orthognathic surgery to reduce postoperative facial edema by its potent anti-inflammatory effect
Trial: NCT06573645
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will be randomized to receive either rituximab 500 mg/m2 or rituximab 375 mg/m2 for six cycles of R-CHOP (21 days per cycle), followed by two maintenance cycles of rituximab (21 days per cycle).
Trial: NCT06763055
Drug: Colchicine 0.5 mg
RxNorm normalized name: colchicine 0.5 MG
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intervention group will receive 0.5mg of oral colchicine daily as soon as possible after randomization, to continue for 30 days.
Trial: NCT06572722
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: atezolizumab adjuvant therapy
Trial: NCT06572722
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nivolumab neoadjuvant therapy
Trial: NCT06763055
Drug: Deferoxamine Mesylate
RxNorm normalized name: Deferoxamine Mesylate
DrugBank: Deferoxamine (DB00746)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intervention group will receive deferoxamine mesylate at a dose of 32mg/kg/day via intravenous infusion immediately (within 1 hour) and continued for 2 consecutive days
Trial: NCT06572722
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: pembrolizumab neoadjuvant+adjuvant therapy
Trial: NCT04776148
Drug: pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion
Trial: NCT04776148
Drug: lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oral capsule
Trial: NCT04776148
Drug: regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: oral tablet
Trial: NCT04776148
Drug: TAS-102 (trifluridine and tipiracil)
RxNorm normalized name: Ta
DrugBank: TAS-102 (DB08937)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT00000979
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000979
Drug: Didanosine
RxNorm normalized name: Didanosine
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05371132
Drug: Zirconium Zr 89-Df-Crefmirlimab
RxNorm normalized name: zirconium
DrugBank: Crefmirlimab (DB17577)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT06173349
Drug: PLZ4-coated paclitaxel loaded micelles (PPM)
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PLZ4-coated paclitaxel loaded micelles intravesically
Trial: NCT06085664
Drug: REGN5678
RxNorm normalized name: Anti-psma/cd28 bispecific antibody regn5678
DrugBank: Nezastomig (DB19061)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by IV (vein)
Trial: NCT06085664
Drug: Piflufolastat F18
RxNorm normalized name: piflufolastat
DrugBank: Piflufolastat F 18 (DB14805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by IV (vein)
Trial: NCT05195034
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The 200ug dexmedetomidine will be diluted into a 50ml syringe and administered with continuous infusion at a rate of 0.2 µg/kg/hour until the end of dural closure.
Trial: NCT04725994
Drug: IDX-1197+XELOX
RxNorm normalized name: alfaxalone
DrugBank: Alfaxalone (DB11371)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose levels will be escalated following a 3+3 dose escalation scheme.
Trial: NCT04725994
Drug: IDX-1197+Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The dose levels will be escalated following a 3+3 dose escalation scheme.
Trial: NCT03539380
Drug: TRx0237
RxNorm normalized name: TRX0237 dimesylate
DrugBank: Hydromethylthionine mesylate (DB16899)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose of TRx0237 16 mg/day (unless enrolled under earlier version of protocol and are on an established dose), with flexible dosing after 3 months (4-16 mg/day)
Trial: NCT05961202
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine 200mg qd
Trial: NCT05905965
Drug: Empagliflozin 20 mg
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients receiving empagliflozin 20 mg daily - experimental arm
Trial: NCT05905965
Drug: Empagliflozin 10 mg
RxNorm normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients receiving empagliflozin 10 mg daily - control arm